Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 16;8(8):1232.
doi: 10.3390/jcm8081232.

Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis

Affiliations
Free PMC article
Review

Telomere Abnormalities in the Pathobiology of Idiopathic Pulmonary Fibrosis

Hasancan Bilgili et al. J Clin Med. .
Free PMC article

Abstract

Idiopathic pulmonary fibrosis (IPF) occurs primarily in older adults and the incidence is clearly associated with aging. This disease seems to be associated with several hallmarks of aging, including telomere attrition and cellular senescence. Increasing evidence suggests that abnormalities involving telomeres and their proteome play a significant role in the pathobiology of IPF. The aim of this study is to summarize present knowledge in the field, as well as to discuss its possible clinical implications. Numerous mutations in genes associated with telomere functioning were studied in the context of IPF, mainly for Telomerase Reverse Transcriptase (TERT) and Telomerase RNA Component (TERC). Such mutations may lead to telomere shortening, which seems to increase the risk of IPF, negatively influence disease progression, and contribute to worse prognosis after lung transplantation. Some evidence indicates the possibility for the use of telomerase activators as potential therapeutic agents in pulmonary fibrosis. To sum up, increasing evidence suggests the role of telomere abnormalities in the pathobiology of IPF, natural history and prognosis of the disease. There are also possibilities for telomerase targeting in the potential development of new treatment agents. However, all these aspects require further research.

Keywords: idiopathic pulmonary fibrosis; lung fibrosis; telomerase; telomere; usual interstitial pneumonia.

Conflict of interest statement

A.J.B. and W.J.P. have been founded by Roche and Boehringer-Ingelheim companies and received travel grants. W.J.P. also received compensation for lectures preparation. Other authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Karakatsani A., Papakosta D., Rapti A., Antoniou K.M., Dimadi M., Markopoulou A., Latsi P., Polychronopoulos V., Birba G., Ch L., et al. Epidemiology of interstitial lung diseases in Greece. Respir. Med. 2009;103:1122–1129. doi: 10.1016/j.rmed.2009.03.001. - DOI - PubMed
    1. Von Plessen C., Grinde O., Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir. Med. 2003;97:428–435. doi: 10.1053/rmed.2002.1466. - DOI - PubMed
    1. Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 1994;150:967–972. doi: 10.1164/ajrccm.150.4.7921471. - DOI - PubMed
    1. Iwai K., Mori T., Yamada N., Yamaguchi M., Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 1994;150:670–675. doi: 10.1164/ajrccm.150.3.8087336. - DOI - PubMed
    1. Scott J., Johnston I., Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ. 1990;301:1015–1017. doi: 10.1136/bmj.301.6759.1015. - DOI - PMC - PubMed
Feedback